Optimizing use of opiates in the management of cancer pain

por Mandalà, Mario, Moro, Cecilia, Labianca, Roberto, Cremonesi, Marco, Barni, Sandro
Publicado 2006

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

por Heinemann, Volker, Boeck, Stefan, Hinke, Axel, Labianca, Roberto, Louvet, Christophe
Publicado 2008

Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer

por Labianca, Alice, Bosetti, Tommaso, Indini, Alice, Negrini, Giorgia, Labianca, Roberto Francesco
Publicado 2020

Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients

por Apolone, Giovanni, Bertetto, Oscar, Caraceni, Augusto, Corli, Oscar, De Conno, Franco, Labianca, Roberto, Maltoni, Marco, Nicora, Mariaflavia, Torri, Valter, Zucco, Furio
Publicado 2006

Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

por Barni, Sandro, Labianca, Roberto, Agnelli, Giancarlo, Bonizzoni, Erminio, Verso, Melina, Mandalà, Mario, Brighenti, Matteo, Petrelli, Fausto, Bianchini, Carlo, Perrone, Tania, Gasparini, Giampietro
Publicado 2011

Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial

por Guida, Michele, Ravaioli, Alessandra, Sileni, Vanna Chiarion, Romanini, Antonella, Labianca, Roberto, Freschi, Antonio, Brugnara, Salvatore, Casamassima, Addolorata, Lorusso, Vito, Nanni, Oriana, Ridolfi, Ruggero
Publicado 2003

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy wi...

por André, Thierry, Iveson, Timothy, Labianca, Roberto, Meyerhardt, Jeffrey A., Souglakos, Ioannis, Yoshino, Takayuki, Paul, James, Sobrero, Alberto, Taieb, Julien, Shields, Anthony F., Ohtsu, Atsushi, Grothey, Axel, Sargent, Daniel J.
Publicado 2013

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in sit...

por Scartozzi, Mario, Bearzi, Italo, Mandolesi, Alessandra, Pierantoni, Chiara, Loupakis, Fotios, Zaniboni, Alberto, Negri, Francesca, Quadri, Antonello, Zorzi, Fausto, Galizia, Eva, Berardi, Rossana, Biscotti, Tommasina, Labianca, Roberto, Masi, Gianluca, Falcone, Alfredo, Cascinu, Stefano
Publicado 2009

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the S...

por Giampieri, Riccardo, Puzzoni, Marco, Daniele, Bruno, Ferrari, Daris, Lonardi, Sara, Zaniboni, Alberto, Cavanna, Luigi, Rosati, Gerardo, Pella, Nicoletta, Zampino, Maria Giulia, Sozzi, Pietro, Germano, Domenico, Zagonel, Vittorina, Codecà, Carla, Libertini, Michela, Labianca, Roberto, Cascinu, Stefano, Scartozzi, Mario
Publicado 2017

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib

por Faloppi, Luca, Bianconi, Maristella, Giampieri, Riccardo, Sobrero, Alberto, Labianca, Roberto, Ferrari, Daris, Barni, Sandro, Aitini, Enrico, Zaniboni, Alberto, Boni, Corrado, Caprioni, Francesco, Mosconi, Stefania, Fanello, Silvia, Berardi, Rossana, Bittoni, Alessandro, Andrikou, Kalliopi, Cinquini, Michela, Torri, Valter, Scartozzi, Mario, Cascinu, Stefano
Publicado 2015

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)

por Ganzinelli, Monica, Rulli, Eliana, Caiola, Elisa, Chiara Garassino, Marina, Broggini, Massimo, Copreni, Elena, Piva, Sheila, Longo, Flavia, Labianca, Roberto, Bareggi, Claudia, Agnese Fabbri, Maria, Martelli, Olga, Fagnani, Daniele, Cristina Locatelli, Maria, Bertolini, Alessandro, Valmadre, Giuseppe, Pavese, Ida, Calcagno, Anna, Giuseppa Sarobba, Maria, Marabese, Mirko
Publicado 2015

Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer

por Giaccherini, Cinzia, Verzeroli, Cristina, Russo, Laura, Gamba, Sara, Tartari, Carmen Julia, Bolognini, Silvia, Schieppati, Francesca, Ticozzi, Chiara, Sarmiento, Roberta, Celio, Luigi, Masci, Giovanna, Tondini, Carlo, Petrelli, Fausto, Giuliani, Francesco, D’Alessio, Andrea, De Braud, Filippo, Santoro, Armando, Labianca, Roberto, Gasparini, Giampietro, Marchetti, Marina, Falanga, Anna
Publicado 2022

Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence

por Gomez-Rosas, Patricia, Pesenti, Marina, Verzeroli, Cristina, Giaccherini, Cinzia, Russo, Laura, Sarmiento, Roberta, Masci, Giovanna, Celio, Luigi, Minelli, Mauro, Gamba, Sara, Tartari, Carmen Julia, Tondini, Carlo, Giuliani, Francesco, Petrelli, Fausto, D'Alessio, Andrea, Gasparini, Giampietro, Labianca, Roberto, Santoro, Armando, De Braud, Filippo, Marchetti, Marina, Falanga, Anna
Publicado 2021

S306: HYPERCOAGULABILITY BIOMARKERS AND THROMBIN GENERATION (TG) PREDICT VENOUS THROMBOEMBOLISM (VTE) IN METASTATIC LUNG CANCER PATIENTS

por Gomez Rosas, Patricia, Marchetti, Marina, Giaccherini, Cinzia, Russo, Laura, Gamba, Sara, Verzeroli, Cristina, Julia Tartari, Carmen, Bolognini, Silvia, Schieppati, Francesca, Ticozzi, Chiara, Sarmiento, Roberta, Celio, Luigi, Masci, Giovanna, Tondini, Carlo, Petrelli, Fausto, Giuliani, Francesco, D’alessio, Andrea, De Braud, Filippo, Santoro, Armando, Labianca, Roberto, Gasparini, Giampietro, Falanga, Anna
Publicado 2023

Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer

por Giaccherini, Cinzia, Marchetti, Marina, Masci, Giovanna, Verzeroli, Cristina, Russo, Laura, Celio, Luigi, Sarmiento, Roberta, Gamba, Sara, Tartari, Carmen J., Diani, Erika, Vignoli, Alfonso, Malighetti, Paolo, Spinelli, Daniele, Tondini, Carlo, Barni, Sandro, Giuliani, Francesco, Petrelli, Fausto, D’Alessio, Andrea, Gasparini, Giampietro, De Braud, Filippo, Santoro, Armando, Labianca, Roberto, Falanga, Anna
Publicado 2020

From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy

por Giampieri, Riccardo, Ziranu, Pina, Daniele, Bruno, Zizzi, Antonio, Ferrari, Daris, Lonardi, Sara, Zaniboni, Alberto, Cavanna, Luigi, Rosati, Gerardo, Casagrande, Mariaelena, Pella, Nicoletta, Demurtas, Laura, Zampino, Maria Giulia, Sozzi, Pietro, Pusceddu, Valeria, Germano, Domenico, Lai, Eleonora, Zagonel, Vittorina, Codecà, Carla, Libertini, Michela, Puzzoni, Marco, Labianca, Roberto, Cascinu, Stefano, Scartozzi, Mario
Publicado 2020

A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients

por Gomez-Rosas, Patricia, Giaccherini, Cinzia, Russo, Laura, Verzeroli, Cristina, Gamba, Sara, Tartari, Carmen Julia, Bolognini, Silvia, Ticozzi, Chiara, Schieppati, Francesca, Barcella, Luca, Sarmiento, Roberta, Masci, Giovanna, Tondini, Carlo, Petrelli, Fausto, Giuliani, Francesco, D’Alessio, Andrea, Minelli, Mauro, De Braud, Filippo, Santoro, Armando, Labianca, Roberto, Gasparini, Giampietro, Marchetti, Marina, Falanga, Anna
Publicado 2023

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

por Iveson, Timothy J., Sobrero, Alberto F., Yoshino, Takayuki, Souglakos, Ioannis, Ou, Fang-Shu, Meyers, Jeffrey P., Shi, Qian, Grothey, Axel, Saunders, Mark P., Labianca, Roberto, Yamanaka, Takeharu, Boukovinas, Ioannis, Hollander, Niels H., Galli, Fabio, Yamazaki, Kentaro, Georgoulias, Vassilis, Kerr, Rachel, Oki, Eiji, Lonardi, Sara, Harkin, Andrea, Rosati, Gerardo, Paul, James
Publicado 2021

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

por Ruzzo, Annamaria, Graziano, Francesco, Galli, Francesca, Galli, Fabio, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Bagaloni, Irene, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Publicado 2019

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

por Ruzzo, Annamaria, Graziano, Francesco, Galli, Francesca, Galli, Fabio, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Bagaloni, Irene, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Publicado 2020